On June 30, 2026, the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) approved US$1.48 million in emergency funding to sustain critical TB and HIV services across Lebanon and Iraq, two countries devastated by a regional humanitarian crisis that has displaced more than 15 million people and severely damaged healthcare infrastructure. The funding response, effective July 1, 2026 through June 30, 2027, marks a critical intervention in a health emergency where key services risk complete collapse without immediate support.
The Crisis: Healthcare Under Siege
The Middle Eastern humanitarian crisis that intensified in 2026 has created unprecedented pressure on health systems in Lebanon and Iraq. In Lebanon alone, renewed hostilities beginning March 2, 2026 have resulted in catastrophic damage to the healthcare system:
- 1 million+ people displaced within the country
- 15 hospitals damaged, 6 completely closed, and 46 primary health care centers shuttered
- 172 attacks on emergency medical services reported through mid-June
- 133 healthcare workers killed and 402 wounded
- 38 health facilities destroyed or seriously damaged
The scope of destruction extends far beyond healthcare. Lebanon's overall conflict-related damages are estimated at USD 14 billion, comprising USD 6.8 billion in physical destruction and USD 7.2 billion in economic losses, with reconstruction needs reaching USD 11 billion.
Iraq faces similar pressures, hosting approximately 1 million internally displaced persons, 350,000 refugees, and 370,000 regional migrants. Supply chains are strained, healthcare access is severely limited in strike zones, and health services are collapsing under the burden of displacement and violence.
Across the entire Eastern Mediterranean Region, 115 million people require humanitarian assistance—nearly half of all people in humanitarian need globally—yet regional health emergency appeals remain 70% underfunded.
The Global Fund Response: Targeted Intervention for TB and HIV
The Global Fund's US$1.48 million emergency allocation focuses on maintaining continuity of TB and HIV treatment services—two diseases particularly vulnerable to collapse in crisis settings. The funding addresses a critical gap: patients cannot interrupt TB treatment without developing drug-resistant TB (a far more costly and lethal condition), and HIV-positive individuals require unbroken antiretroviral therapy to survive.
Funded Interventions
The emergency program includes:
- Diagnostics and laboratory capacity for TB and HIV testing in fragmented health systems
- Sputum transport systems and mobile clinics to reach displaced populations
- TB screening and direct observation therapy (DOT) services
- TB and drug-resistant TB (DR-TB) medicines procurement
- HIV treatment support and community-based TB/HIV outreach
- Nutritional support for TB patients (critical for treatment success)
Implementing Partners
The International Organization for Migration (IOM) will execute the program in collaboration with:
- National health authorities in both countries
- The World Health Organization (WHO)
- Local and international civil society organizations
- Community health networks
Timeline: July 1, 2026 – June 30, 2027 (12-month emergency response cycle)
Procurement Implications: A Multi-Layer Emergency Supply Chain
The Global Fund's intervention creates multiple procurement cascades across three distinct windows:
Layer 1: Medical Supplies and Pharmaceuticals (Immediate, Q3 2026)
Global Fund emergency funding typically sources TB/HIV medicines and diagnostics through WHO-prequalified suppliers and GFATM's own procurement lists, but the crisis context creates demand for expedited procurement channels:
- TB medicines (first-line and DR-TB regimens): local manufacturing partnerships where possible, rapid import where necessary
- HIV antiretroviral therapy (ART): continuation of existing regimens + surge procurement for newly identified cases
- Diagnostic kits (TB Xpert MTB/RIF, HIV rapid tests): high-volume tender through GFATM or direct manufacturer engagement
- Laboratory equipment: repair and replacement of damaged facilities
- Nutritional supplements: protein and energy-dense products for TB patients
Procurement vehicle: GFATM often uses framework agreements with WHO and UNICEF for emergency medical supplies, but supplementary procurement via UNGM (United Nations Global Marketplace) and direct tendering with national health ministries is common.
Layer 2: Health Infrastructure and Logistics (Q3 2026 – Q1 2027)
As the 12-month cycle progresses, procurement shifts toward rebuilding:
- Mobile clinic equipment and deployment logistics
- Cold-chain systems for vaccine and ART storage (many existing facilities damaged)
- Sputum transport containers and PPE (personal protective equipment)
- Transportation and warehousing for distributed supply chains across conflict-affected regions
- Laboratory consumables (reagents, test slides, culture media)
Procurement vehicle: National health ministries with GFATM support; IOM directly for logistics.
Layer 3: Capacity Building and Systems Strengthening (Q4 2026 – Q2 2027)
Complementary spending on:
- Training services for healthcare workers in new facilities
- Information systems and monitoring to track supply chains in fragmented environments
- Consulting services for health system recovery planning
Regional Context: Why This Matters Now
The Global Fund's intervention arrives at a critical juncture. According to the WHO's Middle East Conflict Situation Report (April 2026), health system failure in conflict zones typically follows a predictable trajectory:
- Immediate phase (first 3 months): Healthcare workers killed or displaced, facilities destroyed, emergency supplies looted or destroyed.
- Collapse phase (3-6 months): Secondary infections spike (TB, cholera, malaria) as surveillance falters and treatment access vanishes.
- Long-term crisis phase (6+ months): Drug-resistant infections emerge, child mortality rises, and reconstruction costs explode.
The Global Fund's funding targets the collapse phase, where US$1.48 million in TB/HIV-specific support can prevent a far larger humanitarian and economic catastrophe.
The IOM's multi-country coordination across Lebanon and Iraq also signals a regional approach—recognizing that refugee flows between countries, shared supply chains, and cross-border health security mean that TB/HIV control in one country depends on success in both.
Contractor Entry Points and Strategic Positioning
Development contractors bidding for Global Fund-supported work in this context face specific challenges and opportunities:
Pharmaceutical Suppliers
- WHO prequalification is typically required for TB/HIV medicines (lengthy process—plan 6-12 months if not already listed)
- GFATM framework agreements offer faster pathways for pre-qualified suppliers
- Local manufacturing partnerships (e.g., India-based TB API producers, Egyptian HIV medicine manufacturers) are preferred under Global Fund's localization policy
- Parallel supply chains may be negotiated for conflict zones where standard import routes are disrupted
Logistics and Supply Chain Firms
- IOM procurement for logistics often prioritizes local firms with conflict-zone experience
- Regional logistics hubs (Turkey, Jordan, Egypt) are critical for warehousing and distribution
- Last-mile delivery in fragmented health systems requires on-ground partnerships with local NGOs
Health Systems and Consulting Firms
- Significant consulting demand for health system recovery planning and supply chain design in Q4 2026 – Q1 2027
- Training services for healthcare workers in new facilities or recovered facilities
- Monitoring and evaluation contracts for GFATM's accountability framework
Registration and Compliance
- Contractors must register with UNGM if pursuing IOM sub-contracts
- Engagement with GFATM's accredited service delivery partners (typically NGOs, but some commercial firms qualify)
- Some work may require US Government compliance (USAID Assist, FCPA, sanctions checks) if GFATM financing involves US funding
Looking Ahead: The Broader Reconstruction Pipeline
The Global Fund's US$1.48 million emergency allocation is only the opening salvo of a much larger health reconstruction. Lebanon's USD 11 billion reconstruction need and Iraq's ongoing health system recovery create a multi-year procurement pipeline:
- Health facility rehabilitation (hospitals and primary health care centers)
- Medical equipment procurement (imaging, laboratory, surgical)
- Workforce capacity building (training, management systems)
- Disease surveillance systems (early warning for epidemics in displacement camps)
International development contractors should treat this announcement as a signal of sustained demand for health-focused procurement in the Middle East throughout 2026-2027 and beyond.
The Global Fund's move underscores a key principle in crisis response: preventing the secondary health collapse (drug resistance, opportunistic infections) is far cheaper than managing it. For contractors, that principle translates to sustained funding flows, rapid procurement cycles, and multi-country coordination opportunities across the region.
For More Information
Track procurement opportunities linked to this Global Fund response via:
- Global Fund's grant announcements and project pages (theglobalfund.org)
- IOM's procurement portal (IOM.int/procurement)
- UNGM (United Nations Global Marketplace) for implementing partner tenders
- National health ministry procurement in Lebanon and Iraq
Contractors new to GFATM-financed work should invest in WHO prequalification or GFATM accreditation—the higher upfront bar opens access to a consistent, well-funded pipeline.
---
[Internal Links: Adjust these to match actual BidsFactory page slugs]
- Browse all health and medical tenders
- Explore Middle East procurement opportunities
- Learn more about humanitarian emergency procurement
- Understand the Global Fund as a procurement source
